Data from A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

Autor: James L. Gulley, Jeffrey Schlom, William L. Dahut, Elizabeth C. Jones, Myrna Rauckhorst, Mary Pazdur, Seth M. Steinberg, Philip M. Arlen, Christopher R. Heery, Theresa Ferrara, Jacquin Jones, Caroline Jochems, Diane J. Poole, Ngar-Yee Huen, Ravi A. Madan, Kwong-Yok Tsang, Mahsa Mohebtash

Purpose: PANVAC is a recombinant poxviral vaccine that contains transgenes for MUC-1, CEA, and 3 T-cell costimulatory molecules. This study was conducted to obtain preliminary evidence of clinical response in metastatic breast and ovarian cancer pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fce3deba8bdd7c7796eecf66b09dab2
https://doi.org/10.1158/1078-0432.c.6519708.v1

Mapa T1 e coeficiente de partição do miocárdio em aparelho 3 tesla: comparação entre gadobenato de dimeglumina e gadofosveset trissódico

Autor: Rob J. van der Geest, Songtao Liu, Marcelo Souto Nacif, Fabio Raman, Neville Gai, David A. Bluemke, Jacquin Jones, Christopher T. Sibley

Publikováno v: Radiologia Brasileira, Issue: ahead, Published: 08 JAN 2018
Radiologia Brasileira v.51 n.1 2018
Radiologia Brasileira
Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR)
instacron:CBR
Radiologia Brasileira, Iss 0 (2018)

Objective: To compare an albumin-bound gadolinium chelate (gadofosveset trisodium) and an extracellular contrast agent (gadobenate dimeglumine), in terms of their effects on myocardial longitudinal (T1) relaxation time and partition coefficient. Mate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad37575cc80e056f3b26a065998d9e2
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842018005001101&lng=en&tlng=en

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

Autor: Alex Sparreboom, William D. Figg, Charity D. Scripture, Jacquin Jones, Neil Desai, Erin R. Gardner, Jeanny B. Aragon-Ching, William L. Dahut, Michael J. Hawkins

Publikováno v: Clinical Cancer Research. 14:4200-4205

Purpose: Abraxane (ABI-007) is a 130-nm albumin-bound (nab) particle formulation of paclitaxel, devoid of any additional excipients. We hypothesized that this change in formulation alters the systemic disposition of paclitaxel compared with conventio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce95a974a5dccadc4c364f094b2f9a1b
https://doi.org/10.1158/1078-0432.ccr-07-4592

Sample size calculation for clinical trials using cardiac magnetic resonance partition coefficient and extracellular volume fraction for the assessment of diffuse myocardial fibrosis

Autor: Peter Kellman, Jacquin Jones, Songtao Liu, Marcelo Souto Nacif, David A. Bluemke, Nadine Kawel, Christopher T. Sibley, Jing Han

Publikováno v: Journal of Cardiovascular Magnetic Resonance
Journal of Cardiovascular Magnetic Resonance, Vol 15, Iss Suppl 1, p P39 (2013)

Methods A modified Look-Locker with inversion recovery (MOLLI) sequence was used to determine myocardial T1 values pre-, and 12 and 25 min post-administration of a gadolinium-based contrast agent at 3 Tesla. For 24 healthy subjects (8 men; 29±6 year

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d41ad8664f29914e1952ed4ae497ae0f
https://doi.org/10.1186/1532-429x-15-s1-p39

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

Autor: Jacquin Jones, William L. Dahut, James L. Gulley, Susan Halabi, Matteo Vergati, John J. Wright, Howard L. Parnes, James W. Hodge, Clara C. Chen, Lisa Skarupa, Seth M. Steinberg, Elizabeth C. Jones, Mary Pazdur, Philip M. Arlen, Kwong-Yok Tsang, Diane J. Poole, Jeffrey Schlom, Ravi A. Madan, Jack P. Higgins, Vittore Cereda

Publikováno v: Cancer immunology, immunotherapy : CII. 59(5)

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p=0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study repor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d228226b41e77b08f8079859164de244
https://pubmed.ncbi.nlm.nih.gov/20635924